S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Federal student loan payments are starting again. Here's what you need to know
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
66,000% upside on tiny biotech? (Ad)
A fight over precious groundwater in a rural California town is rooted in carrots
Indonesia is set to launch Southeast Asia's first high-speed railway, largely funded by China
NASDAQ:ZGNX

Zogenix (ZGNX) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$26.68
▼
$26.68
50-Day Range
$26.10
▼
$26.68
52-Week Range
$11.03
▼
$26.90
Volume
94 shs
Average Volume
3.76 million shs
Market Capitalization
$1.50 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

ZGNX stock logo

About Zogenix (NASDAQ:ZGNX) Stock

Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA.


ZGNX Stock News Headlines

July 6, 2023 | fool.com
Alcon (NYSE: ALC)
May 21, 2023 | morningstar.com
Longeveron Inc Ordinary Shares - Class A
October 1, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
October 11, 2022 | businesswire.com
How Women Lead #GetonBoard Week Honorees Are Helping Catapult Fearless Women Leaders into Board Seats - Business Wire
September 30, 2022 | forbes.com
Biocryst Pharmaceuticals
September 26, 2022 | marketscreener.com
Nippon Shinyaku : Fintepla® (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet syndrome - Marketscreener.com
September 13, 2022 | marketscreener.com
PROMIS NEUROSCIENCES INC. : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
September 10, 2022 | bizjournals.com
How Women Lead appoints three new executive board members - Bizwomen - The Business Journals
October 1, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
September 9, 2022 | bizjournals.com
East Bay Biotech Companies - San Francisco Business Times - The Business Journals
September 9, 2022 | prnewswire.com
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - PR Newswire
September 8, 2022 | streetinsider.com
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - StreetInsider.com
September 7, 2022 | finance.yahoo.com
Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors - Yahoo Finance
August 30, 2022 | bizjournals.com
With early-cancer detection technology, Delfi Diagnostics looks to beat out Guardant Health, Illumina's Grail and others - San Francisco Business Times - The Business Journals
August 29, 2022 | thestreet.com
Depomed Reports Dip in Earnings, Reduces Revenue Guidance
August 23, 2022 | prnewswire.com
Delfi Diagnostics Adds Finance and Market Access Leadership as It Prepares for Commercial Launch - PR Newswire
August 16, 2022 | businesswire.com
Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - Business Wire
August 15, 2022 | streetinsider.com
Nuvig Therapeutics Expands Leadership Team with the Appointment of Dr. Joanne Quan as Chief Medical Officer - StreetInsider.com
August 9, 2022 | businesswire.com
Dravet Syndrome Treatment Market Report 2022-2029: Stiripentol and Cannabidiol to Contribute to Significant Growth of 11.7% - ResearchAndMarkets.com - Business Wire
August 3, 2022 | streetinsider.com
Tevard Biosciences Appoints Zoya Ignatova to Its Scientific Advisory Board - StreetInsider.com
August 2, 2022 | prnewswire.com
Geno Hires First Chief Legal Officer on Path to Accelerate the Transition to More Sustainable Materials - PR Newswire
July 28, 2022 | marketscreener.com
UCB : Strong first six months – UCB with continued delivery and strong resilience - Marketscreener.com
June 25, 2022 | gurufocus.com
Adamis Appoints Vickie Reed to Board of Directors - GuruFocus.com
June 24, 2022 | marketscreener.com
UCB : updates financial guidance for 2022 while maintaining 2025 financial guidance - Marketscreener.com
June 8, 2022 | businesswire.com
ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology - Business Wire
June 8, 2022 | seekingalpha.com
UCB's therapy gets FDA orphan drug status to treat seizures linked with rare epilepsy - Seeking Alpha
June 7, 2022 | streetinsider.com
ADARx Pharmaceuticals Expands Leadership Team, Appointing Andrew Seacat as Head of Toxicology - StreetInsider.com
See More Headlines
Receive ZGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zogenix and its competitors with MarketBeat's FREE daily newsletter.

ZGNX Company Calendar

Last Earnings
11/04/2021
Today
10/01/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ZGNX
CUSIP
98978L10
CIK
1375151
Web
www.zogenix.com
Phone
(510) 550-8300
Fax
858-259-1166
Employees
218
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($4.07)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-209,380,000.00
Net Margins
-278.38%
Pretax Margin
-278.26%
Return on Equity
-91.20%
Return on Assets
-43.60%

Debt

Debt-to-Equity Ratio
0.88
Current Ratio
3.63
Quick Ratio
4.74

Sales & Book Value

Annual Sales
$81.69 million
Price / Sales
18.36
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.64 per share
Price / Book
4.02

Miscellaneous

Outstanding Shares
56,227,000
Free Float
53,922,000
Market Cap
$1.50 billion
Optionable
Optionable
Beta
0.89
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Stephen James FarrStephen James Farr
    President, Chief Executive Officer & Director
  • Ashish M. Sagrolikar
    Chief Operating Officer & Executive Vice President
  • Michael Patrick Smith
    Chief Financial Officer, Treasurer & Executive VP
  • Bradley S. Galer
    Chief Medical Officer & Executive Vice President
  • Steven A. Johnson
    Vice President, Legal Council & Compliance Office

Key Competitors

View All Competitors













ZGNX Stock - Frequently Asked Questions

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.96) by $0.08. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $22.71 million. Zogenix had a negative trailing twelve-month return on equity of 91.20% and a negative net margin of 278.38%. The business's revenue for the quarter was up 690.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.02) earnings per share.

What is Stephen Farr, Ph.D.'s approval rating as Zogenix's CEO?

7 employees have rated Zogenix Chief Executive Officer Stephen Farr, Ph.D. on Glassdoor.com. Stephen Farr, Ph.D. has an approval rating of 85% among the company's employees.

What other stocks do shareholders of Zogenix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals (GWPH), Gilead Sciences (GILD), Vanda Pharmaceuticals (VNDA), AbbVie (ABBV), QUALCOMM (QCOM), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Southwest Airlines (LUV) and Micron Technology (MU).

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $26.68.

How much money does Zogenix make?

Zogenix (NASDAQ:ZGNX) has a market capitalization of $1.50 billion and generates $81.69 million in revenue each year. The company earns $-209,380,000.00 in net income (profit) each year or ($4.07) on an earnings per share basis.

How many employees does Zogenix have?

The company employs 218 workers across the globe.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The official website for the company is www.zogenix.com. The company can be reached via phone at (510) 550-8300, via email at ir@zogenix.com, or via fax at 858-259-1166.

This page (NASDAQ:ZGNX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -